click below
click below
Normal Size Small Size show me how
Specialty Pharmacy
Inflammatory Conditions
| Brand | Generic | Basic Info |
|---|---|---|
| Cosentxy | secukinumab | MOA: IL-17 inhibitor Indications: Plaque Psoriasis, Psoriatic Arthritis Administration(general): SubQ, Monthly Unique ADES: IBD exacerbation/new onset |
| Enbrel | etanercept | MOA: TNF inhibitor Indications: Plaque Psoriasis, Psoriatic Arthritis,RA,JIA Administration(general): SubQ, weekly Unique ADEs: Cardiac,CNS Biosimilar: Erelzi |
| Humira | adalimumab | MOA: TNF inhibitor Indications: Plaque Psoriasis, Psoriatic Arthritis,RA, IBD,JIA,+ Administration(general):SubQ, Q2 Week Unique ADEs: Cardiac,CNS Biosimilars:Amjevita and Cyltezo |
| Otezla | aprimilast | MOA: PDE-4 inhibitor Indications: Plaque Psoriasis, Psoriatic Arthritis Administration(general): PO, BID Unique ADEs: GI (severe), Psych Titration pack available |
| Remicade | infliximab | MOA: TNF inhibitor Indications: Plaque Psoriasis, Psoriatic Arthritis,RA,IBD,JIA,+ Administration(general): IV, Q2 month Unique ADEs: Cardiovascular, CNS, infusion reaction (premedicate) Biosimilars: Renflexis, Inflectra |
| Siliq | brodalumab | MOA: IL-17 inhibitor Indications: Plaque Psoriasis Administration(general): SubQ, Q2 week Unique ADEs: Suicidal Ideation (BBW and REMS), IBD exacerbation/new onset |
| Stelara | ustekinumab | MOA: IL-12,23 inhibitor Indications: Plaque Psoriasis, Psoriatic Arthritis,IBD Administration(general):SubQ, Q3 months Unique ADEs: Neurotoxicity (RPLS) |
| Taltz | ixekizumab | MOA: IL-17 inhibitor Indications: Plaque Psoriasis Administration(general): SubQ, Monthly Unique ADES: IBD exacerbation/new onset |
| Tremfya | guselkumab | MOA: IL-23 inhibitor Indications: Plaque Psoriasis Administration(general): SubQ, Q2 months |
| Cimzia | certolizumab | MOA: TNF inhibitor Indications:, Psoriatic Arthritis,RA, IBD,+ Administration(general): SubQ, monthly Unique ADEs: Anemias, CNS, Cardiac |
| Simponi | golimumab | MOA: TNF inhibitor Indications:Psoriatic Arthritis,RA, IBD,+ Administration(general):SubQ,monthly Unique ADEs: Anemias, CNS, Cardiac |
| Actemra | tocilzumab | MOA: IL-6 inhibitor Indications: RA Administration(general): SUbQ, Weekly |
| Kineret | anakinra | MOA: IL-1 inhibitor Indications: RA, + Administration(general): SubQ,daily Unique ADEs: Neuotrophilia(SEVERE) monitor monthly x 3 months, then q3months |
| Orencia | abatacept | MOA: T-cell costim-blocker Indications: Psoriatic Arthritis,RA Administration(general):SubQ, weekly Unique ADEs: Worse outcomes in COPD patients |
| Xeljanx | tofactinib | MOA: JAK STAT inhibitor Indications: RA,IBD Administration(general):PO, BID (QD for XR) Unique ADES: Bradycard/arrythmia, anemias(dose adjust),liver injury(monitor),lipids (monitor) Renal and Hepatic Dosing- 5mg QD |
| Entyvio | vedolizumab | MOA: CAM-1 inhibitor Indications: IBD Administration(general):IV, Q2 months Unique ADES: Liver injury, PML |
| Inflammatory Conditions Generalizations: Methotrexate OKAY do NOT double up biologics TNF blockers 1st line biologics | Vaccinate before initiation: NO LIVE VACCINES during therapy. Avoid in Preg/BF Many also used for Ankylosing spondylitis | Warnings for: Infection, Malignancy TB testing, HepB/C, testing SubQ: Refrigerate, don't freeze or shake. Thigh,back of arm, abdomen(rotate) |